BORONIC ACID ADDUCTS OF TECHNETIUM-99M DIOXIME COMPLEXES

Abstract: Boronic acid adducts of technetium-99m dioxime complexes are useful for imaging the myocardium, hepatobiliary system, brain and blood pool in humans and other mammalian species.

Description: Brief Description of the Invention Boronic acid adducts of technetium-99m dioxime complexes having the formula I 99m Tc X(Y)₃ Z are useful as imaging agents in humans and other mammalian species. In formula I, and throughout the specification, the symbols are as defined below. X is an anion; Y is a vicinal dioxime having the formula or a pharmaceutically acceptable salt thereof, and R₁ and R₂ are each independently hydrogen, halogen, alkyl, aryl, amino or a 5 or 6-membered nitrogen or oxygen containing heterocycle, or together R₁ and R₂ are -(CR₈R₉) n - wherein n is 3, 4, 5 or 6 and R₈ and R₉ are each independently hydrogen or alkyl; Z is a boron derivative having the formula III B-R₃ wherein R₃ is hydroxy, alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkoxy, carboxyalkyl (preferably having 2 to 19 carbons), carboxyalkenyl (preferably having 4 to 19 carbons), hydroxyalkyl, hydroxy­ alkenyl, alkoxyalkyl, alkoxyalkenyl, haloalkyl, haloalkenyl, aryl, arylalkyl or (R₄R₅N)-alkyl and R₄ or 6 and R₈ and R₅ are each independently hydrogen, alkyl, or arylalkyl, or R₄ and R₅ when taken together with the nitrogen atom to which they are attached form a 5 or 6-membered nitrogen containing heterocycle. Listed below are definitions of the terms used to describe the complexes of this invention. These definitions apply to the terms as they are used throughout the specification (unless they are otherwise limited in specific instances) either individually or as part of a larger group. The terms "alkyl" and "alkoxy" refer to both straight and branched chain groups. Those groups having 1 to 10 carbon atoms are preferred. The terms "alkenyl" refers to both straight and branched chain groups. Those groups having 2 to 10 carbon atoms are preferred. The term "aryl" refers to phenyl and substituted phenyl. Preferred are phenyl and phenyl substituted with 1, 2 or 3 alkyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, alkoxyalkyl, halogen, amino, hydroxy, or formyl groups. Additional exemplary aryl groups for the distance wherein R₃ is aryl include 3-(5-dimethylamino-1-naphthalenesulfonylamino)phenyl, 3-[4-[3'-phenyl-2'-pyrazolin-1,1'-yl]benzenesulfonyl­ amino]phenyl, 3-(pyrenesulfamido)phenyl, 3-[4-(4-­ dimethylamino-1-naphthylazo)-3-(methoxyphenyl­ sulfamido)phenyl, 3-[4-(4-dimethylamino-1-­ phenylazo)phenylthioureido]phenyl. Preferred "cycloalkyl" and "cycloalkenyl" groups are those having 5, 6 or 7 carbon atoms. The terms include those groups substituted with alkyl, alkoxy, aryl, carboxyalkyl, arylalkyl or (R₄R₅N)-alkyl groups. The terms "halide", "halo" and "halogen" refer to fluorine, chlorine, bromine and iodine. The expression "5 or 6-membered nitrogen containing heterocycle" refers to all 5 and 6-membered rings containing at least one nitrogen atom. Exemplary aliphatic groups are dehydro derivatives of a compound having the formula wherein m is 0 or 1 and A is O, N-R₆ or CH-R₆ wherein R₆ is hydrogen, alkyl, aryl or arylalkyl. Such groups include pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, 4-alkyl­ piperazinyl, 4-alkylpiperidinyl, and 3-alkyl­ pyrrolidinyl groups. Also included within the expression "5 or 6-membered nitrogen containing heterocycle" are aromatic groups. Exemplary aromatic groups are pyrrolyl, imidazolyl, oxazolyl, pyrazolyl, pyridinyl, and pyrimidinyl groups. The above groups can be linked via a hetero atom or a carbon atom. The expression "5 or 6-membered nitrogen or oxygen containing heterocycle" refers to all 5 and 6-membered rings containing at least one nitrogen or oxygen atom. Exemplary groups are those described above under the definition of the expression "5 or 6-membered nitrogen containing heterocycle". Additional exemplary groups are 1,4-dioxanyl and furanyl. Detailed Description of the Invention Preparation of the complexes of this invention can best by accomplished using technetium-99m in the form of the pertechnetate ion. The pertechnetate ion can be obtained from commercially available technetium-99m parent-­ daughter generators; such technetium is in the +7 oxidation state. The generation of the pertechnetate ion using this type of generator is well known in the art, and is described in more detail in United States patents 3,369,121 and 3,920,995. These generators are usually eluted with saline solution and the pertechnetate ion is obtained as the sodium salt. To prepare the complexes of this invention, pertechnetate ion (in the form of a salt) is combined with a source of anion, a boronic acid derivative having the formula or a pharmaceutically acceptable salt thereof, wherein R₇ is hydrogen, alkyl or aryl, and a dioxime having the formula or a pharmaceutically acceptable salt thereof. It is possible, in some instances, to prepare a boronic acid derivative of formula IV in situ . For example, when preparing a complex having an alkoxy group attached to the boron atom, it is possible to utilize boric acid and the appropriate alkanol as reactants. The source of the anion moiety (X) can be water or it can be an acid or salt which dissociates to release an appropriate anion. Exemplary anionic moieties are hydroxyl, halide, isothiocyanato (N=C=S ϑ ) and thiocyanato (S-C=N ϑ ). The preferred anionic moieties are the halides, and chloride is the most preferred halide. If the source of the anion is not water, the source should be present in an appropriate concentration to compete effectively with any water that may be present during the reaction. It has been found that the source of anion should be present in the reaction mixture in a concentration of about 0.3 to 4.5 molar. The boronic acid derivative of formula IV should preferably be present in a concentration of about 5 to 200 millimolar. The dioxime of formula II should be preferably be present in a concentration of about 9 to 43 millimolar. The formation of the complex proceeds best if the mixture of pertechnetate ion, source of anion, boronic acid derivative, and dioxime is heated at about 25°C to 150°C for about 5 minutes to about 60 minutes, preferably at about 100°C to about 140°C for about 5 minutes to about 15 minutes. The reaction is preferably run in an aqeuous medium at a pH of less than, or equal to, about 5. The reaction mixture should also contain a reducing agent. Stannous ion is the preferred reducing agent, and can be introduced in the form of a stannous salt such as a stannous halide ( e.g. , stannous chloride or stannous fluoride). The reducing agent should be present in a concentration of about 1.5 micromolar to 6.6 millimolar. Various complexing agents (also known in the art as chelating agents) can be included as part of the complexing reaction. The complexing agent should, of course, be pharmaceutically acceptable. Exemplary complexing agents are diethylenetriamine-pentaacetic acid (DTPA), ethylene glycol-bis(β-aminoethyl ether)-N,N'-­ tetraacetic acid (EGTA), ethylenediamine tetra­ acetic acid (EDTA), citric acid, tartaric acid, malonic acid, etc. The complexing reaction mixture can also include an accelerator (catalyst) which serves to improve the radiochemical purity ( i.e. , per cent of the radioactivity that is in the desired chemical form) of the product. Exemplary accelerators are the α-hydroxycarboxylic acids such as citric acid, tartaric acid, and malonic acid. A combination of DTPA and citric acid has been found to be preferred. Working with the technetium-99 isotope, the structure of complexes of this invention has been investigated and is believed to be: Because of the short half-life of technetium-­ 99m ( i.e. , 6.02 hours), it is necessary to prepare the complexes of this invention at, or near, the site where they are to be used. A kit having all of the components, other than the pertechnetate ion, needed to prepare the boronic adducts of technetium-99m dioxime complexes of formula I is an integral part of this invention. Such a kit contains a source of anion, a boronic acid derivative of formula IV (or compounds which can react in situ to form such a derivative), or a pharmaceutically acceptable salt thereof, a dioxime of formula II, or a pharmaceutically acceptable salt thereof, and a reducing agent. It may optionally contain a complexing agent. The kits of this invention can be formulated in aqueous solution. To optimize the stability of the kit, and to optimize the radiochemical purity of the labeled product, the pH of the kit should be adjusted to fall within the range of about 2.0 to 5.5 using a pharmaceutically acceptable acid or base ( e.g. , hydrochloric acid or sodium hydroxide). Preferably, the pH of the kit will be about 3.0. It is also preferred that the kit be in lyophilized form. While "wet" kits can be used, they are not as efficacious as the corresponding lyophilized kit. The complexes of this invention are useful as imaging agents. More specifically, they are useful for imaging the myocardium and the hepatobiliary system in humans and other mammalian hosts. Those complexes of this invention which are neutral at physiological pH ( i.e. , pH 7.4) are also useful for imaging the brain in humans and other mammalian hosts. [The charge of the complexes of this invention is determined by the sum of the charges of the organic groups ("R₁", "R₂" and "R₃") attached to the boron atom and part of the dioximes.] Those complexes of this invention which contain the vicinal dioxime 1,2-ethanedione dioxime are also useful for imaging the blood pool of humans and other mammalian hosts. The complexes of this invention can be administered to a host by bolus intravenous injection. The size of the host, and the imaging system used, will determine the quantity of radioactivity needed to produce diagnostic images. For a human host, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of technetium-99m. The following example of specific embodiments of this invention. Example 1 99mTc (chlorine)(dimethyl glyoxime)₃ methoxy boron and 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron Into a 5ml siliconized serum vial were measured 5.0 mg of dimethyl glyoxime, 0.5ml of methanol, 2.0 mg of boric acid and 0.5 mg of stannous chloride in 5µl of concentrated hydro­ chloric acid. Sodium pertechnetate (The sodium pertechnetate used in these examples is obtained by eluting a sterile technetium-99m generator with physiological saline.) in physiological saline (0.2 ml) was added to the vial which was then heated at 140°C for 30 minutes yielding 6% (As used in these examples, the yield is determined by HPLC and is reported as the percent of radioactivity eluted in the desired form.) of the 99mTc (chlorine)(dimethyl glyoxime)₃t methoxy boron as determined by HPLC (high pressure liquid chromatography). The reaction also yielded 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron. The complexes were separated by HPLC. Example 2 99mTc (chlorine)(dimethyl glyoxime)₃ ethoxy boron and 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron Into a 5ml siliconized vial were measured 2.0 mg of dimethyl glyoxime in 0.2 ml of ethanol, 2.0 mg of boric acid, 10mg of citric acid in 0.1ml of water, 100mg of sodium chloride, 1.0mg of diethylenetetramine pentaacetic acid, and approximately 50-60µg of anhydrous stannous chloride in lµl of concentrated hydrochloric acid. Sodium pertechnetate in physiological saline (0.5ml) was added to the vial which was then heated at 100°C for 5 minutes yielding 4-5% of 99mTc (chlorine)(dimethyl glyoxime) ethoxy boron. The reaction also yielded 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron. The complexes were separated by HPLC. Example 3 99mTc (chlorine)(dimethyl glyoxime)₃ propyloxy boron and 99mTc (chlorine)(dimethyl glyoxime)₃-­ hydroxy boron. Following the procedure of example 1, but substituting n-propanol for methanol, yielded 99mTc (chlorine)(dimethyl glyoxime)₃ ethoxy boron. The reaction also yielded 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron. The complexes were separated by HPLC. Example 4 99mTc (chlorine)(dimethyl glyoxime)₃ butyloxy boron and 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron Following the procedure of example 1, but substituting n-butanol for methanol, yielded 6% of 99mTc (chlorine)(dimethyl glyoxime)₃ ethoxy boron. The reaction also yielded 99mTc (chlorine)-­ (dimethyl glyoxime)₃ hydroxy boron. The complexes were separated by HPLC. Example 5 99mTc (chlorine)(dimethyl glyoxime)₃ pentyloxy boron and 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron Following the procedure of example 1, but substituting n-pentanol for methanol, yielded 99mTc (chlorine)(dimethyl glyoxime)₃ ethoxy boron. The reaction also yielded 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron. The complexes were separated by HPLC. Example 6 99mTc (chlorine)(dimethyl glyoxime)₃ hexyloxy boron and 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron Following the procedure of example 1, but substituting n-hexanol for methanol, yielded 8% of 99mTc (chlorine)(dimethyl glyoxime)₃ ethoxy boron. The reaction also yielded 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron. The complexes were separated by HPLC. Example 7 99mTc (chlorine)(dimethyl glyoxime)₃ octyloxy boron and 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron Following the procedure of example 1, but substituting n-octanol for methanol, yielded 12% 99mTc (chlorine)(dimethyl glyoxime)₃ ethoxy boron. The reaction also yielded 99mTc (chlorine)(dimethyl glyoxime)₃hydroxy boron. The complexes were separated by HPLC. Example 8 99mTc (chlorine)(dimethyl glyoxime)₃ 1-methylpropyl boron Following the procedure of example 2, but substituting 1-methylpropane boronic acid for boric acid, yielded the title complex. Example 9 99mTc (chlorine)(dimethyl glyoxime)₃ methyl boron Into a 5ml siliconized serum vial were measured 2.0mg of dimethyl glyoxime in 0.2 ml of ethanol, 2.0mg of methane boronic acid, 10mg of citric acid in 0.1ml of water, 100mg of sodium chloride, 1.0mg of diethylenetetramine pentaacetic acid, and about 50-60µg of stannous chloride in 1µl of concentrated hydrochloric acid. Sodium pertechnetate in physiological saline (0.5ml) was added to the vial which was heated at 100°C for 5 minutes yielding 80-90% of the title complex. Example10 99mTc (chlorine)(dimethyl glyoxime)₃ propyl boron Following the procedure of example 9, but substituting 1-propane boronic acid for methane boronic acid, yielded the title complex. Example 11 99mTc (chlorine)(dimethyl glyoxime)₃ butyl boron Following the procedure of example 9, but substituting 1-butane boronic acid for methane boronic acid, yielded the title complex. Example 12 99mTc (chlorine)(dimethyl glyoxime)₃ pentyl boron Following the procedure of example 9, but substituting 1-pentane boronic acid for methane boronic acid, yielded 85% of the title complex. Example 13 99mTc (chlorine)(dimethyl glyoxime)₃ hexyl boron Into a 5ml siliconized serum vial were measured 3.0mg of dimethyl glyoxime, 20mg of 1-hexane boronic acid, sodium pertechnetate in physiological saline (0.2ml) and 50µl of saturated aqueous stannous tartrate. The vial was heated at 140°C for 5 minutes yielding 16% of the title complex. Example 14 99mTc (chlorine)(dimethyl glyoxime)₃ heptyl boron Following the procedure of example 9, but substituting 8.0mg of 1-heptane boronic acid for methane boronic acid and substituting 50µl of saturated aqeuous stannous tartrate for stannous chloride in hydrochloric acid, yielded 85% of the title complex. Example 15 99mTc (chlorine)(dimethyl glyoxime)₃ phenyl boron Following the procedure of example 2, but substituting benzene boronic acid for boric acid, yielded 88% of the title complex. Example 16 99mTC (chlorine) (dimethyl glyoxime)₃ butyl boron Into a 5ml siliconized serum vial were measured 1.0mg of dimethyl glyoxime in 0.1ml of ethanol, 5.0mg of 1-butane boronic acid in 50µl of ethanol, 0.3 ml of saturated aqueous sodium chloride and 25µl of saturated stannous pyro­ phosphate. Sodium pertechnetate in physiological saline (0.1ml) was added to the vial which was heated at 140°C for 5 minutes yielding 70% of the title complex. Example17 99mTc (bromine)(dimethyl glyoxime)₃ butyl boron Into a 5ml siliconized serum vial were measured 1.0mg of dimethyl glyoxime in 0.1ml of ethanol, 5.0mg of 1-butane boronic acid in 50µl of ethanol, 0.3ml of saturated aqueous potassium bromide, and 25µl of saturated aqueous stannous pyrophosphate. Sodium pertechnetate in physiological saline (0.1ml) was added to the vial which was heated at 140°C for 5 minutes yielding 59% of the title complex. Example 18 99mTc (iodine)(dimethyl glyoxime)₃ butyl boron Into a 5ml siliconized serum vial were measured 1.0mg of dimethyl glyoxime in 0.1ml of ethanol, 5.0mg of 1-butane boronic acid in 50µl of ethanol, 0.3ml of saturated aqueous potassium iodide, 25 µl of saturated aqueous stannous pyrophosphate. Sodium pertechnetate in physiological saline (0.1ml) was added to the vial which was heated at 140°C for 5 minutes yielding 23% of the title complex. Example 19 99mTc (fluorine)(dimethyl glyoxime)₃ butyl boron Into a 5ml siliconized serum vial were measured 1.0mg of dimethyl glyoxime in 0.1ml of ethanol, 5.0mg 1-butane boronic acid in 50µl of ethanol, 0.3ml of saturated aqueous sodium fluoride, and 25µl of saturated aqeuous stannous pyrophosphate. Sodium pertechnetate in physiological saline (0.2ml) was added to the vial which was heated at 140°C for 5 minutes yielding 0.6% of the title complex. Example 20 99mTc (chlorine)(dimethyl glyoxime)₃ 3-amino­ phenyl boron Into a 5ml siliconized serum vial were measured 5.0mg of dimethyl glyoxime in methanol, 30mg of 3-aminobenzene boronic acid, and 0.5mg of stannous chloride in 5µl of concentrated hydro­ chloric acid. Sodium pertechnetate in physiological saline (0.2ml) was added to the vial which was heated at 140°C for 5 minutes yielding 50% of the title complex. Example 21 99mTc (chlorine)(dimethyl glyoxime)₃ 4-methyl­ phenyl boron Following the procedure of example 2, but substituting p -toluene boronic acid for boric acid, yielded 88% of the title complex. Example 22 99mTc (chlorine)(dimethyl glyoxime)₃ 3-(1-piperi­ dinyl)propyl boron Into a 5ml siliconized serum vial were measured 0.5mg of dimethyl glyoxime in 0.1ml of ethanol 1.0mg of 3-(1-piperidinyl)propane boronic acid monohydrochloride, 0.2ml of saturated sodium chloride, 10mg of citric acid, and 50µl of saturated aqueous stannous pyrophosphate. Sodium pertechnetate in physiological saline (0.2ml) was added to the vial which was heated at 100°C for 5 minutes yielding 75% of the title complex. Example 23 99mTc (bromine)(dimethyl glyoxime)₃ 3-(1-piperi­ dinyl)propyl boron Into a 5ml siliconized serum vial were measured 1.0mg of dimethyl glyoxime in 0.1ml of ethanol, 5.0mg of 3-(1-piperidinyl) propane boronic acid monohydrochloride, 0.4ml of saturated potassium bromide, 10mg of citric acid, and 50µl of saturated aqueous stannous pyrophosphate. Sodium pertechnetate in physiological saline (0.2ml) was added to the vial which was heated at 100°C for 5 minutes yielding 13.8% of the title complex. Example 24 99mTc (chlorine)(dimethyl glyoxime)₃ 3-(4-methyl-1-­ piperidinyl)propyl boron Following the procedure of example 23, but substituting 0.2ml of saturated sodium chloride for potassium bromide and 5.0mg of 3-(4-methyl-­ 1-piperidinyl) propane boronic acid monohydro­ chloride for 3-(1-piperidinyl)propane boronic acid monohydrochloride, yielded 94% of the title complex. Example 25 99mTc (chlorine)(dimethyl glyoxime)₃ 3-(4-­ morpholinyl) propyl boron Following the procedure of example 23, but substituting 0.2ml of saturated sodium chloride for potassium bromide and 5.0mg of 3-(4-morpho­ linyl)propane boronic acid monohydrochloride for 3-(1-piperidinyl) propane boronic acid mono­ hydrochloride, yielded 87% of the title complex. Example 26 99mTc (chlorine)(dimethyl glyoxime)₃ 3-(4-benzyl­ piperidinyl)propyl boron Following the procedure of example 23, but substituting 0.2ml of saturated sodium chloride for potassium bromide and 5.0mg of 3-(4-benzyl-1-­ piperidinyl) propane boronic acid monohydrochloride for 3-(1-piperidinyl) propane boronic acid mono­ hyrochloride, yielded the title complex. Example 27 99mTc (chlorine)(dimethyl glyoxime)₃ 3-(5-dimethyl­ amino-1-naphthalenesulfonylamino)phenyl boron Following the procedure of example 23, but substituting 0.2ml of saturated sodium chloride for potassium bromide and 5.0mg of 3-(5-dimethyl­ amino-1-naphthalenesulfonylamino) benzene boronic acid monohydrochloride for 3-(1-piperidinyl) propane boronic acid monohydrochloride, yielded the title complex. Example 28 99mTc (chlorine)(dimethyl glyoxime)₃ 3-[methyl(2-­ phenylethyl)amino] propyl boron Following the procedure of example 23, but substituting 0.2ml of saturated sodium chloride for potassium bromide and 5.0mg of 3-(methyl(2-­ phenylethyl)amino) propane boronic acid for 3-(1-­ piperidinyl)propane boronic acid monohydrochloride, yielded the title complex. Example 29 99mTc (chlorine)(dimethyl glyoxime)₃ 4-hydroxy-1-­ butenyl boron Following the procedure of example 2, but substituting 4-hydroxy-1-butene boronic acid for boric acid, yielded the title compound. Example 30 99mTc (chlorine)(dimethyl glyoxime)₃ (4-benzyl-­ 1-piperidinyl) boron Following the procedure of example 22, but substituting 5mg of (4-benzyl-1-piperidinyl) boronic acid monohydrochloride for 3-(1-piperi­ dinyl) propane boronic acid monohydrochloride yielded 83% of the title complex. Example 31 99mTc (chlorine)(dimethyl glyoxime)₃ 4-(bromo­ methyl)phenyl boron and 99mTc (chlorine) (dimethyl glyoxime)₃ 4-(ethoxymethyl)phenyl boron Following the procedure of example 22, but substituting 1mg of 4-(bromomethyl)benzene boronic acid for 3-(1-piperidinyl)propane boronic acid, monohydrochloride, yielded less than 5% of 99mTc (chlorine)(dimethyl glyoxime)₃ 4-(bromo­ methyl)phenyl boron. The reaction also yielded 99mTc (chlorine) (dimethyl glyoxime)₃ 4-(ethoxy­ methyl)phenyl boron. The complexes were separated by HPLC. Example 32 99mTc (chlorine)(dimethyl glyoxime)₃ 2-phenyl­ ethyl boron Following the procedure of example 2, but substituting 2-phenylethane boronic acid for boric acid, yielded the title complex. Example 33 99mTc (chlorine)(dimethyl glyoxime)₃ 4-(methoxy­ methyl)phenyl boron Following the procedure of example 22, but substituting 1mg of 4-(bromomethyl)benzene boronic acid for 3-(1-piperidinyl)propane boronic acid monohydrochloride and methanol for ethanol, yielded the title complex. Example 34 99mTc (chlorine)(dimethyl glyoxime)₃ 4-(butyloxy­ methyl)phenyl boron Following the procedure of example 22, but substituting 1mg of 4-(bromomethyl)benzene boronic acid for 3-(1-piperidinyl)propane boronic acid monohydrochloride and butanol for ethanol, yielded the title complex. Example 35 99mTc (chlorine) (1,2-cycloheptanedione dioxime)₃ methyl boron Following the procedure of example 9, but substituting 1,2-cycloheptenedione dioxime for dimethyl glyoxime, yielded 92% of the title complex. Example 36 99mTc (chlorine)(dimethyl glyoxime)₃ 4-[(diethyl­ amino)methyl]phenyl boron Following the procedure of example 2, but substituting 4-[(diethylamino)methyl]benzene boronic acid monohydrochloride for boric acid, and adding 2.0 mg of diethylenetriamine pentacetic acid yielded 77% of the title complex. Example 37 99mTc (chlorine)(dimethyl glyoxime)₃ 4-(amino­ methyl)phenyl boron Following the procedure of example 2, but substituting 4-(aminoethyl)boronic acid mono­ hydrochloride for 4-[(diethylamino)methyl]benzene boronic acid monohydrochloride, yielded 81% of the title complex. Example 38 99mTc (chlorine)(dimethyl glyoxime)₃ hexadecyl boron Following the procedure of example 36, but substituting hexadecane boronic acid for 4-[(-diethylamino)methyl]benzene boronic acid monohydrochloride, yielded the title complex. Example 39 99mTc (chlorine)(dimethyl glyoxime)₃ 17-octa­ decenoic acid, 18-boron Following the procedure of example 2, but substituting 18-borono-17-octadecenoic acid for boric acid, yielded 62% of the title complex. Example 40 99mTc (chlorine)(dimethyl glyoxime)₃ 4-formyl­ phenyl boron Following the procedure of example 2, but substituting p-(benzaldehyde)boronic acid for boric acid, yields 47% of the title complex. Example 41 99mTc (chlorine)(dimethyl glyoxime)₃ 4-[[methyl (2-phenylethyl)amino]methyl]phenyl boron Following the procedure of example 2, but substituting 4-[[methyl(2-phenylethyl)amino]-­ methyl]benzene boronic acid monohydrochloride for boric acid, yielded the title complex. Example 42 99mTc (chlorine)(dimethyl glyoxime)₃ 4-ethyl­ phenyl boron Following the procedure of example 2, but substituting 4-ethylbenzene boronic acid for boric acid, yielded the title complex. Example 43 99mTc (chlorine)(dimethyl glyoxime)₃ 2,4-dimethyl­ phenyl)boron Following the procedure of example 2, but substituting 2,4-dimethylbenzene boronic acid for boric acid, yielded the title complex. Example 44 99mTc (chlorine)(dimethyl glyoxime)₃ 4-[(dimethyl­ amino)methyl]phenyl boron Following the procedure of example 2, but substituting 4-[(dimethylamino)methyl]benzene boronic acid monohydrochloride for boric acid, yielded the title complex. Example 45 99mTc (chlorine)(dimethyl glyoxime)₃ 4-[(diiso­ propylamino)methyl]phenyl boron Following the procedure of example 2, but substituting 4-[(diisopropylamino)methyl]benzene boronic acid monohydrochloride for boric acid, yielded the title complex. Example 46 99mTc (chlorine)(1,2-cyclohexanedione)₃ 3-­ (1-piperidinyl)propyl boron Into a 5ml siliconized vial were measured 0.5mg of 1,2-cyclohexanedione dioxime in 0.1ml of ethanol, 1.0mg of 3-(1-piperidinyl)propane boronic acid monohydrochloride, 0.2ml of saturated sodium chloride, 10mg of citric acid and 50µl of saturated stannous pyrophosphate. Sodium pertechnetate in physiological saline (0.2ml) was added to the vial which was then heated at 100°C for 5 minutes yielding 84% of the title complex. Example 47 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃l­ 3-(4-methyl-1-piperidinyl)propyl boron Following the procedure of example 46, but substituting 3-(4-methyl-1-piperidinyl)propane boronic acid monohydrochloride for 3-(1-piperi­ dinyl)propane boronic acid monohydrochloride, yielded 82% of the title complex. Example 48 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃l­ 3-(4-morpholinyl)propyl boron Following the procedure of example 46, but substituting 3-(4-morpholinyl)propane boronic acid monohydrochloride for 3-(1-piperidinyl)propane boronic acid monohydrochloride, yielded 90% of the title complex. Example 49 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃l­ 3-aminophenyl boron Following the procedure of example 46, but substituting 3-aminobenzene boronic acid monohydrochloride for 3-(1-piperidinyl)propane boronic acid monohydrochloride yielded 93% of the title complex. Example 50 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃l­ 3-(4-phenyl-1-piperidinyl) propyl boron Following the procedure of example 46, but substituting 5.0mg of 3-(4-phenyl-1-piperidinyl)­ propane boronic acid monohydrochloride for 3-(1-­ piperidinyl)propane boronic acid monohydrochloride and labeling with sodium pertechnetate in physio­ logical saline (0.3ml), yielded 84% of the title complex. Example 51 99mTc (bromime)(1,2-cyclohexanedione dioxime)₃ 3-(4-phenyl-1-piperidinyl) propyl boron Following the procedure of example 46, but substituting 5.0mg of 3-(4-phenyl-1-piperidinyl)­ propane boronic acid monohydrochloride for 3-(1-­ piperidinyl)propane boronic acid monohydrochloride and 100mg of potassium bromide for sodium chloride yielded the title complex. Example 52 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃l­ 1-butyl boron Following the procedure of example 46, but substituting 1-butane boronic acid for 3-(piperi­ dinyl)propane boronic acid monohydrochloride and labeling with sodium pertechnetate in physiological saline (0.3ml) yielded 69% of the title complex. Example 53 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃l­ 3-(5-dimethylamino-1-naphthalenesulfonylamino)-­ phenyl boron Following the procedure of example 46, but substituting 3-(5-dimethylamino-1-naphthalene­ sulfonylamino)benzene boronic acid for 3-(1-piper­ idinyl)propane boronic acid monohydrochloride and labeling with sodium pertechnetate in physiological saline (0.3ml), yielded 80% of the title complex. Example 54 99mTc (chlorine)(1,2-ethanedione dioxime)₃ 3-­ (5-dimethylamino-1-naphthalenesulfonylamino)phenyl boron Following the procedure of example 53, but substituting 1,2-ethanedione dioxime for 1,2-cyclohexanedione dioxime, yielded 71% of the title compound. Example 55 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃l­ methyl boron Into a 5ml siliconized serum vial were measured 2.0mg of 1,2-cyclohexanedione dioxime in 0.2ml of ethanol, 2.0mg of methane boronic acid, 10mg of citric acid, 100mg of sodium chloride, 1.0mg of diethylenetriamine pentaacetic acid, and 50-60µg of anhydrous stannous chloride in 1µl of concentrated hydrochloric acid. Sodium pertechnetate in physiological saline (0.5ml) was added to the vial which was then heated at 100°C for 5 minutes yielding 85% of the title complex. Example 56 99mTc (bromine)(1,2-cyclohexanedione dioxime)₃ methyl boron Following the procedure of example 55, but substituting potassium bromide for sodium chloride and labeling with sodium pertechnetate in physiological saline (0.1ml), yielded the title complex. Example 57 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃l­ 4-ethylphenyl boron Following the procedure of example 55, but substituting 4-ethylbenzene boronic acid for methane boronic acid, yielded the title complex. Example 58 99mTc (chlorine)(dimethyl glyoxime)₃ 4-[1-(diiso­ propylamino)ethyl]phenyl boron Following the procedure of example 2, but substituting 4-[1-(diisopropylamino)ethyl] benzene boronic acid for boric acid, yielded the title complex. Example 59 99mTc (chlorine)(dimethyl glyoxime)₃ 4-[(isopropyl­ amino)methyl]phenyl boron Following the procedure of example 2, but substituting 4-[(isopropylamino)methyl]benzene boronic acid monohydrochloride for boric acid, yielded 8% of the title complex. Example 60 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃yl­ 4-methylphenyl boron Following the procedure of example 2, but substituting 4-toluene boronic acid for boric acid and 1,2-cyclohexanedione dioxime for dimethyl glyoxime, yielded the title complex. Example 61 99mTc (chlorine)(dimethyl glyoxime)₃ 2,4,6-tri­ methylphenyl boron Following the procedure of example 2, but substituting 2,4,6-trimethylbenzene boronic acid for boric acid, yielded the title complex. Example 62 99mTc (chlorine)(dimethyl glyoxime)₃ 2-methyl-1-­ propyl boron Following the procedure of example 2, but substituting 2-methyl-1-propane boronic acid for boric acid, yielded 84% of the title complex Example 63 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃­ 1-heptyl boron Following the procedure of example 2, but substituting 1-heptane boronic acid for boric acid and 1,2-cyclohexanedione dioxime for dimethyl glyoxime, yielded the title complex. Example 64 99mTc (chlorine)(dimethyl glyoxime)₃ 9-carboxy­ nonyl boron Following the procedure of example 2, but substituting 10-borono decanoic acid for boric acid, yielded the title complex. Example 65 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃­ 2-methyl-1-propyl boron Following the procedure of example 2, but substituting 2-methyl-1-propane boronic acid for boric acid and 1,2-cyclohexanedione dioxime for dimethyl glyoxime, yield 85% of the title complex. Example 66 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃­ ethyl boron Following the procedure of example 2, but substituting ethane boronic acid for boric acid and 1,2-cyclohexanedione dioxime for dimethyl glyoxime, yielded 88% of the title complex. Example 67 99mTc (chlorine)(dimethyl glyoxime)₃ ethyl boron Following the procedure of example 2, but substituting ethane boronic acid for boric acid, yielded 77% of the title complex. Example 68 99mTc (chlorine)(dimethyl glyoxime)₃ 3-methyl­ phenyl boron Following the procedure of example 2, but substituting 3-toluene boronic acid for boric acid yielded the title complex. Example 69 99mTc (chlorine)(dimethyl glyoxime)₃ 2-methyl­ phenyl boron Following the procedure of example 2, but substituting o -toluene boronic acid for boric acid yielded the title complex. Example 70 99mTc (chlorine)(dimethyl glyoxime)₃ cyclopentyl boron Following the procedure of example 2, but substituting cyclopentane boronic acid for boric acid, yielded the title complex. Example 71 99mTc (chlorine)(dimethyl glyoxime)₃ 2-butyl boron Following the procedure of example 2, but substituting 2-butane boronic acid for boric acid, yielded the title complex. Example 72 99mTc (chlorine)(dimethyl glyoxime)₃ 4-methoxy­ phenyl boron Following the procedure of example 2, but substituting 4-methoxybenzene boronic acid for boric acid, yielded the title complex. Example 73 99mTc (chlorine)(dimethyl glyoxime)₃ 4-( t -butyl)-­ phenyl boron Following the procedure of example 2, but substituting 4-( t -butane)benzene boronic acid for boric acid, yielded the title complex. Example 74 99mTc (chlorine)(1,2-ethanedione dioxime)₃ 1-butyl boron Following the procedure of example 2, but substituting 1-butane boronic acid for boric acid 1,2-ethanedione dioxime for dimethyl glyoxime yielded 76% of the title complex. Example 75 99mTc (chlorine)(dimethyl glyoxime)₃ 4-(2-propyl)-­ phenyl boron Following the procedure for example 2, but substituting 4-(2-propane)benzene boronic acid for boric acid, yielded the title complex. Example 76 99mTc (chlorine)(1,2-cyclohexanedione dioxime)₃)-­ hydroxy boron Following the procedure of example 2, but substituting 1,2-cyclohexanedione dioxime for dimethyl glyoxime, and omitting ethanol, yielded the title complex. Example 77 99mTc (chlorine)(α-furyldioxime)₃ methyl boron Following the procedure of example 2, but substituting α-furyldioxime for dimethyl glyoxime and methane boronic acid for boric acid, yielded the title complex. Example 78 99mTc (chlorine)(3-methyl-1,2-cyclopentanedione dioxime)₃ methyl boron Following the procedure of example 2, but substituting 3-methyl-1,2-cyclopentanedione dioxime for dimethyl glyoxime and methane boronic acid for boric acid, yielded the title complex. Example 79 99mTc (chlorine)(1,2-cyclopentanedione dioxime)₃ methyl boron Following the procedure of example 2, but substituting 1,2-cyclopentanedione dioxime for dimethyl glyoxime, and methane boronic acid for boric acid, yielded the title complex.

Claims: 1. A boronic acid adduct of technetium-99m dioxime complexes having the formula 99mTc X(Y)₃ Z, wherein X is an anion; Y is a vicinal dioxime having the formula or a pharmaceutically acceptable salt thereof, wherein R₁ and R₂ are each independently hydrogen, halogen, alkyl, aryl, amino or a 5 or 6-membered nitrogen or oxygen containing heterocycle, or together R₁ and R₂ are -(CR₈R₉)n- wherein n is 3, 4, 5 or 6 and R₈ and R₉ are each independently hydrogen or alkyl; and Z is a boron derivative of the formula B-R₃ wherein R₃ is hydroxy, alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkoxy, carboxyalkyl, carboxyalkenyl, hydroxyalkyl, hydroxyalkenyl, alkoxyalkyl, alkoxy­ alkenyl, haloalkyl, haloalkenyl, aryl, arylalkyl or (R₄R₅N)-alkyl and R₄ and R₅ are each independently hydrogen, alkyl, or arylalkyl, or R₄ and R₅ when taken together with the nitrogen atom to which they are attached form a 5 or 6-membered nitrogen containing heterocycle. 2. A boronic acid adduct in accordance with claim 1, wherein X is a halide. 3. A boronic acid adduct in accordance with claim 1, wherein X is chloride or bromide. 4. A boronic acid adduct in accordance with claim 1, wherein X is chloride. 5. A boronic acid adduct in accordance with claim 1, wherein Y is dimethyl glyoxime, 1,2-cyclohexanedione dioxime,1,2-ethanedione dioxime, α-furyldioxime, 1,2-cyclopentanedione dioxime, or 3-methyl-1,2-cyclopentanedione dioxime. 6. A boronic acid adduct in accordance with claim 1, wherein Y is dimethyl glyoxime. 7. A boronic acid adduct in accordance with claim 1, wherein Y is 1,2-cyclohexanedione dioxime. 8. A boronic acid adduct in accordance with claim 1, wherein Y is 1,2-ethanedione dioxime. 9. A boronic acid adduct in accordance with claim 1, wherein Y is a α-furyldioxime. 10. A boronic acid adduct in accordance with claim 1, wherein the boron derivative Z is B-alkyl. 11. A boronic acid adduct in accordance with claim 1, wherein the boron derivative Z is B-alkoxy. 12. A boronic acid adduct in accordance with claim 1, wherein the boron derivative Z is B-benzyl. 13. A boronic acid adduct in accordance with claim 1, wherein the boron derivative Z is B-cycloalkyl. 14. A boronic acid adduct in accordance with claim 1, 99mTc (chlorine)(1,2-cyclohexane­ dione)₃ methyl boron. 15. The boronic acid adduct in accordance with claim 1, 99mTc (chlorine)(dimethyl glyoxime)₃ 1-methylpropyl boron. 16. The boronic acid adduct in accordance with claim 1, 99mTc (chlorine)(dimethyl glyoxime)₃ 4-methylphenyl boron. 17. The boronic acid adduct in accordance with claim 1, 99mTc (chlorine)(dimethyl glyoxime)₃ cyclopentyl boron. 18. The boronic acid adduct in accordance with claim 1, 99mTc (chlorine)(1,2-cyclohexane­ dione)₃ ethyl boron. 19. The boronic acid adduct in accordance with claim 1, 99mTc (chlorine)(dimethyl glyoxime)₃ 4-(t-butyl)phenyl boron. 20. A kit suitable for labeling with technetium-99m, said kit comprising: (i) a source of anion; (ii) a boronic acid derivative, or compounds which can react insitu to form a boronic acid derivative, having the formula or a pharmaceutically acceptable salt thereof, wherein R₃ is hydroxy, alkyl, alkenyl, cycloalkyl, cycloalkenyl,alkoxy,carboxyalkyl,carboxyalkenyl, hydroxyalkyl, hydroxyalkenyl, alkoxyalkyl, alkoxy­ alkenyl, haloalkyl, haloalkenyl, aryl, arylalkyl, or R₄R₅N-alkyl and R₄and R₅ are each independently hydrogen, alkyl, or arylalkyl, or R₄ and R₅ when taken together with nitrogen atom to which they are attached form a 5 or 6-membered nitrogen containing heterocycle, and R₇ is hydrogen, alkyl or aryl; (iii) a dioxime having the formula or a pharmaceutically acceptable salt thereof, wherein R₁ and R₂ are each independently hydrogen, halogen, alkyl, aryl, amino or a 5 or 6-membered nitrogen or oxygen containing heterocycle, or together R₁ and R₂ are -(CR₈R₉)n- wherein n is 3, 4, 5 or 6 and R₈ and R₉ are each independently hydrogen or alkyl; and (iv) a reducing agent. 21. A kit in accordance with claim 20, wherein the source of anion is a source of halide. 22. A kit in accordance with claim 20, wherein the source of anion is a source of chloride or bromide. 23. A kit in accordance with claim 20 wherein the dioxime is dimethyl glyoxime, 1,2-­ cyclohexanedione, 1,2,-ethanedione dioxime or α-furyldioxime. 24. A kit in accordance with claim 20, wherein the dioxime is dimethyl glyoxime. 25. A kit in accordance with claim 20, wherein the dioxime is 1,2-cyclohexanedione. 26. A kit in accordance with claim 20, wherein the reducing agent is a stannous salt.

Inventors: FELD, THOMAS A., NUNN, ADRIAN D., TREHER, ELIZABETH N.
Applicants: E.R. SQUIBB & SONS, INC.
Application year: 1986
Main classification: C07F13
IPC codes: A61K51, C07F13, G21G4